

Product Name: BAY 87-2243 Revision Date: 07/04/2024 **Product Data Sheet**

BAY 87-2243

Cat. No.:	B1115
CAS No.:	1227158-85-1
Formula:	C26H26F3N7O2
M.Wt:	525.53
Synonyms:	
Target:	Angiogenesis
Pathway:	HIF
Storage:	Store at -20°C

Solvent &	Solubility			Achie Perfet	
	insoluble in H2O; ≥	8.24 mg/mL in EtOH with ultras	onic; ≥8.76 mg/m	L in DMSO	
In Vitro	Preparing	Mass Solvent Concentration	1mg	5mg	10mg
	Biock Solutions	1 mM	1.9028 mL	9.5142 mL	19.0284 mL
		5 mM	0.3806 mL	1.9028 mL	3.8057 mL
		10 mM	0.1903 mL	0.9514 mL	1.9028 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

HIF-1 inhibitor, potent and selective

IC₅₀ & Target

Cell	Viab	ility	Assa

IC ₅₀ & Target		Blow
	Cell Viability Assay	Charles Inc. In
	Cell Line:	H460, RCC4 cells, BRAFWT melanoma cells, and BRAFV600E melanoma cells
In Vitro	Preparation method:	Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
	Reacting conditions:	1, 10, 100, and 1000 nmol/L BAY 87-2243 for 16 h; or 10 nmol/L BAY 87-2243
		A Lynnyr oport com

1 | www.apexbt.com

		for 24, 48, and 72 h
	Applications:	BAY 87-2243 (100 nmol/L) significantly inhibited the expression of HIF target
		gene, including ANGPTL4, ADM, and CA9 in hypoxic H460 cells. Moreover,
		BAY 87-2243 inhibited mitochondrial complex I and induced cell death of
	B Jongoon	melanoma cells in a dose-dependent manner.
	Animal experiment	P Fallence
	Animal models:	H460 xenograft tumors model; melanoma xenografts (G-361 and
		SK-MEL-28); patient-derived (MEXF 276 and MEXF 1732) melanoma
		xenograft tumors model
	Dosage form:	0.5, 1.0, 2.0, and 4.0 mg/kg, oral administration, once daily, for 21 days; or 9
		mg/kg, oral gavage (p.o.)., once a day
In Vivo	Applications:	BAY 87-2243 dose-dependently decreased tumor weight, hypoxia-inducible
		factor (HIF)-1a protein, and HIF-1 target gene expression levels in H460
		xenograft tumors. Moreover, BAY 87-2243 significantly reduced tumor growth
	Bure unerown	in all BRAF mutant melanoma xenografts.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
	Annesper	slightly differ with the theoretical value. This is caused by an experimental
		system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

Ellinghaus, P., Heisler, I., Unterschemmann, K., Haerter, M., Beck, H., Greschat, S., Ehrmann, A., Summer, H., Flamme, I., Oehme, F., Thierauch, K., Michels, M., Hess-Stumpp, H. and Ziegelbauer, K. (2013) BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2, 611-6242
Schockel, L., Glasauer, A., Basit, F., Bitschar, K., Truong, H., Erdmann, G., Algire, C., Hagebarth, A., Willems, P. H., Kopitz, C., Koopman, W. J. and Heroult, M. (2015) Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab. 3, 11

APENBIO

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage **2** | www.apexbt.com

temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.





APExBIO Technology

www.apexbt.com 7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com













